Labiotech.eu

News and Trends 31 May 2017

German Biotech Enters the Clinic with Next-Generation Antibody for AML

Synimmune has hit the clinic with a first-in-human study of its Fc-optimized antibody FlySyn to treat patients with acute myeloid leukemia (AML). The German biotech Synimmune is developing next-generation anti-cancer antibodies to treat rare blood cancers. Its lead asset, FlySyn, is an antibody directed against the human fms-like tyrosine kinase 3 (FLT3) for the treatment of patients with […]

May 31, 2017 - 2 minutesmins - By Melanie De Almeida

News and Trends 31 May 2017

Swiss Biotech raises €9M to Treat Sudden Hearing Loss in Phase III

Strekin has closed a Series C financing round that will fund the progression of its lead candidate for hearing loss to Phase III. Based in Basel, Strekin focuses on repurposing existing drugs by discovering new mechanisms of action. The company has now received €9.2M (CHF 10M) in Series C to fund the company’s activity until 2019 […]

May 31, 2017 - 1 minutemin - By Clara Rodríguez Fernández

Interview 31 May 2017

Poll: Academia, Biotech or Another Career? How Industry Leaders Decided

Inspired by Philip’s interview with Patrick Baeuerle, who traversed academia, entrepreneurship and finance, I collected thoughts from biotech leaders on choosing a direction. Morten Sommer Professor of Systems Biology, TU Denmark Founder of Biosyntia, AntibioTx, Microlytic There’s a lot of freedom in academia that allows you to explore things that don’t have to be immediately […]

May 31, 2017 - 3 minutesmins - By Evelyn Warner

News and Trends 30 May 2017

Swiss Researchers get to the Genetic Bottom of Kidney Cancer

Researchers from the University of Zurich have established a new mouse model of kidney cancer that could further our understanding of this deadly disease. Clear cell renal cell carcinoma (ccRCC) is the most common form of kidney cancer and in roughly half of the patients with this disease the tumor develops metastasis and can’t be […]

May 30, 2017 - 2 minutesmins - By Melanie De Almeida

More News! 30 May 2017

FDA Fast Tracks Muscular Dystrophy Drug backed by Woodford

The FDA has handed out a Fast Track Designation to AMO Pharma for its key asset AMO-02 to treat congenital myotonic dystrophy. The British-American biotech hybrid AMO Pharma is advancing a small pipeline of drugs for rare genetic disorders. The biotech, which is backed by famous UK Investor Neil Woodford, is currently pushing its lead candidate […]

May 30, 2017 - 2 minutesmins - By Melanie De Almeida

geneva biotech serono university of geneva

Best in Biotech 30 May 2017

In Geneva, the Capital of Peace, 10 Biotechs Are Putting up a Fight

Geneva is the largest city in French-speaking Switzerland, a financial powerhouse, home to the United Nations and known as the “Peace Capital.” Can the city’s biotech industry justify its high profile? Geneva rose to recognition as a biotech hub in 2006, when Serono sealed its acquisition by Merck in the city’s biggest-ever licensing plan. However, a late-stage […]

May 30, 2017 - 7 minutesmins - By Denise Neves Gameiro

Interview 29 May 2017

Meet the Founder of the UK’s Best Biotech that Discovered Humira

Meet the founder of three hot British biotechs developing antibody-related technologies. Despite his interest in business, he remains an academic at heart. Sir Greg Winter is one of the biggest names in European biotech. As a Professor of Biochemistry at Cambridge University, he developed phage display technology that became the foundation of his first company in […]

May 29, 2017 - 9 minutesmins - By Evelyn Warner

trust me im an artist amsterdam bioart exhibition

News and Trends 27 May 2017

“Trust me, I’m an Artist” Explores the Ethics of Biotech in Amsterdam

The exhibition in Amsterdam showcases the works of ten bioartists questioning the huge complexity of ethics in the rapidly developing field of biotechnology. The Waag Society has brought together bioartists from all over Europe that explore topics like gene editing, antibiotics, human tissue culture, public health and personalized medicine. After a series of performances discussed […]

May 27, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 26 May 2017

UPDATE: UK Cannabis Biotech ready for a Blockbuster in Rare Epilepsy

UPDATE (26/05/2017): GW has released more positive results in The New England Journal of Medicine demonstrating that Epidiolex dramatically reduces convulsive seizures in children with Dravet syndrome. The results have primed the drug for its NDA submission to the FDA and led some to forecast blockbuster success. Original Publication 30/03/2016 GW Pharmaceuticals (UK) has announced positive results […]

May 26, 2017 - 4 minutesmins - By Ekaterina Perets

News and Trends 25 May 2017

Resilient Tumor Cells Drive Breast Cancer Relapse in Mice

Tumor cells that survive chemotherapy and drive breast cancer relapse may provide drug targets for potential treatments to reduce the recurrence. In mice, some breast tumor cells can survive chemotherapy and drive the recurrence of tumor, found a team of researchers from the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany and in Monterotondo, Italy; […]

May 25, 2017 - 3 minutesmins - By External Contributor

Interview 25 May 2017

How Biotech Will Make Us Live Longer – Let’s Talk Anti-Aging

Last week, at our first Labiotech Hangout, Philip had a chat with James Peyer, a partner at Apollo Ventures, to ask a few questions about how biotech is tackling the anti-aging space. For a long time, the anti-aging field has not seen much innovation, both due to a lack of scientific know-how as well as a lack of […]

May 25, 2017 - 4 minutesmins - By Melanie De Almeida

Interview 25 May 2017

Cross-Innovation in Healthcare – Discussing Trends and Challenges

At Bionnale in Berlin last week, Joachim moderated a panel discussion on the topic of cross-innovation in biotech. Here’s our recap. Cross-innovation is key to areas like biotech and healthcare, bringing together different industries to generate new solutions. Although the companies represented at the recent cross-innovation panel were coming from very distinct fields, the three panelists had a […]

May 25, 2017 - 4 minutesmins - By Melanie De Almeida

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

German Biotech Enters the Clinic with Next-Generation Antibody for AML

Swiss Biotech raises €9M to Treat Sudden Hearing Loss in Phase III

Poll: Academia, Biotech or Another Career? How Industry Leaders Decided

Swiss Researchers get to the Genetic Bottom of Kidney Cancer

FDA Fast Tracks Muscular Dystrophy Drug backed by Woodford

In Geneva, the Capital of Peace, 10 Biotechs Are Putting up a Fight

Meet the Founder of the UK’s Best Biotech that Discovered Humira

“Trust me, I’m an Artist” Explores the Ethics of Biotech in Amsterdam

UPDATE: UK Cannabis Biotech ready for a Blockbuster in Rare Epilepsy

Resilient Tumor Cells Drive Breast Cancer Relapse in Mice

How Biotech Will Make Us Live Longer – Let’s Talk Anti-Aging

Cross-Innovation in Healthcare – Discussing Trends and Challenges

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!